Co-Authors
This is a "connection" page, showing publications co-authored by BRUCE MINSKY and CULLEN TANIGUCHI.
Connection Strength
3.367
-
Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. Adv Radiat Oncol. 2021 Nov-Dec; 6(6):100763.
Score: 0.199
-
Food and Drug Administration approvals in phase 3 Cancer clinical trials. BMC Cancer. 2021 Jun 12; 21(1):695.
Score: 0.198
-
Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. Adv Radiat Oncol. 2021 Mar-Apr; 6(2):100621.
Score: 0.190
-
Gastrointestinal malignancies and supportive care trials: a snapshot of the last two decades. BMJ Support Palliat Care. 2022 Mar; 12(1):42-45.
Score: 0.188
-
Patient-Reported GI Outcomes in Patients With Anal Cancer Receiving Modern Chemoradiation. JCO Oncol Pract. 2020 12; 16(12):e1524-e1531.
Score: 0.185
-
Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials. Oncologist. 2024 Jul 05; 29(7):547-550.
Score: 0.061
-
Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States. Cancer Med. 2024 Jun; 13(12):e7434.
Score: 0.061
-
Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume. JNCI Cancer Spectr. 2024 Apr 30; 8(3).
Score: 0.060
-
Long-Term Patient-Reported Dyspareunia After Definitive Chemoradiation for Anal Cancer: Using the Anterior Vaginal Wall as an Organ-at-Risk to Define an Actionable Dosimetric Goal. Adv Radiat Oncol. 2024 May; 9(5):101449.
Score: 0.059
-
Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy. Eur J Cancer. 2023 11; 194:113357.
Score: 0.058
-
Prevalence, trends, and characteristics of trials investigating local therapy in contemporary phase 3 clinical cancer research. Cancer. 2023 11 01; 129(21):3430-3438.
Score: 0.057
-
Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials. JAMA Netw Open. 2023 05 01; 6(5):e2313819.
Score: 0.056
-
Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis. Oncologist. 2023 04 06; 28(4):327-332.
Score: 0.056
-
HPV-related anal cancer is associated with changes in the anorectal microbiome during cancer development. Front Immunol. 2023; 14:1051431.
Score: 0.056
-
Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases. Liver Cancer. 2023 Aug; 12(3):198-208.
Score: 0.056
-
Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer. Cancers (Basel). 2023 Mar 10; 15(6).
Score: 0.056
-
Patient-reported Bowel Function and Bowel-related Quality of Life After Pelvic Radiation for Rectal Adenocarcinoma: The Impact of Radiation Fractionation and Surgical Resection. Clin Colorectal Cancer. 2023 06; 22(2):211-221.
Score: 0.055
-
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453.
Score: 0.053
-
Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2022 09 01; 114(1):163-172.
Score: 0.053
-
Patient-Reported Sexual Function in Long-Term Survivors of Anal Cancer Treated With Definitive Intensity Modulated Radiation Therapy and Concurrent Chemotherapy. Pract Radiat Oncol. 2022 Sep-Oct; 12(5):e397-e405.
Score: 0.053
-
Patient-Reported Bowel and Urinary Function in Long-Term Survivors of Squamous Cell Carcinoma of the Anus Treated With Definitive Intensity Modulated Radiation Therapy And Concurrent Chemotherapy. Int J Radiat Oncol Biol Phys. 2022 09 01; 114(1):78-88.
Score: 0.053
-
Microbiome Dynamics During Chemoradiation Therapy for Anal Cancer. Int J Radiat Oncol Biol Phys. 2022 08 01; 113(5):974-984.
Score: 0.053
-
Patient-Reported Outcomes After Chemoradiation in Patients With Anal Cancer: A Qualitative Analysis. Adv Radiat Oncol. 2022 Jul-Aug; 7(4):100986.
Score: 0.053
-
Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer. Clin Transl Radiat Oncol. 2022 Jul; 35:9-16.
Score: 0.052
-
Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. Cancer. 2022 07 01; 128(13):2529-2539.
Score: 0.052
-
Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. Oncologist. 2022 02 03; 27(1):40-47.
Score: 0.052
-
Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunol Res. 2022 02; 10(2):259-271.
Score: 0.052
-
NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Clin Transl Radiat Oncol. 2022 Mar; 33:66-69.
Score: 0.051
-
Intraoperative Radiation After Pelvic Short Course Radiation-Based Total Neoadjuvant Therapy for Patients With Rectal Adenocarcinoma at High Risk for Local Recurrence. Clin Colorectal Cancer. 2022 09; 21(3):204-211.
Score: 0.051
-
Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. J Pers Med. 2021 Dec 01; 11(12).
Score: 0.051
-
The radiotherapy quality assurance gap among phase III cancer clinical trials. Radiother Oncol. 2022 01; 166:51-57.
Score: 0.051
-
Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clin Colorectal Cancer. 2022 03; 21(1):e28-e37.
Score: 0.051
-
Prognostic impact of lymphopenia and neutrophil-lymphocyte ratio for patients with anal squamous cell carcinoma. J Gastrointest Oncol. 2021 Oct; 12(5):2412-2422.
Score: 0.050
-
Impact factor and citation metrics in phase III cancer trials. Oncotarget. 2021 Aug 31; 12(18):1780-1786.
Score: 0.050
-
Dosimetric Uncertainties Resulting From Interfractional Anatomic Variations for Patients Receiving Pancreas Stereotactic Body Radiation Therapy and Cone Beam Computed Tomography Image Guidance. Int J Radiat Oncol Biol Phys. 2021 12 01; 111(5):1298-1309.
Score: 0.050
-
CEA as a blood-based biomarker in anal cancer. Oncotarget. 2021 May 25; 12(11):1037-1045.
Score: 0.049
-
A Machine Learning Model Approach to Risk-Stratify Patients With Gastrointestinal Cancer for Hospitalization and Mortality Outcomes. Int J Radiat Oncol Biol Phys. 2021 09 01; 111(1):135-142.
Score: 0.049
-
Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. J Hepatocell Carcinoma. 2021; 8:57-69.
Score: 0.048
-
Performance Status Restriction in Phase III Cancer Clinical Trials. J Natl Compr Canc Netw. 2020 10; 18(10):1322-1326.
Score: 0.047
-
Professional Medical Writer Assistance in Oncology Clinical Trials. Oncologist. 2020 11; 25(11):e1812-e1815.
Score: 0.047
-
Sponsor-involved statistical analyses in Phase III cancer clinical trials. Int J Cancer. 2020 12 15; 147(12):3579-3581.
Score: 0.046
-
Pathologic Response and Postoperative Complications After Short-course Radiation Therapy and Chemotherapy for Patients With Rectal Adenocarcinoma. Clin Colorectal Cancer. 2020 06; 19(2):116-122.
Score: 0.045
-
IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer. Adv Radiat Oncol. 2020 May-Jun; 5(3):369-376.
Score: 0.044
-
Assessment of setup uncertainty in hypofractionated liver radiation therapy with a breath-hold technique using automatic image registration-based image guidance. Radiat Oncol. 2019 Aug 30; 14(1):154.
Score: 0.044
-
Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies. Clin Transl Radiat Oncol. 2019 Nov; 19:59-65.
Score: 0.044
-
Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. VideoGIE. 2019 May; 4(5):223-225.
Score: 0.043
-
Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiother Oncol. 2019 04; 133:54-61.
Score: 0.042
-
Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 2018 10; 7(10):4880-4892.
Score: 0.041
-
Hyperfractionated abdominal reirradiation for gastrointestinal malignancies. Radiat Oncol. 2018 Aug 07; 13(1):143.
Score: 0.041
-
Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):595-600.
Score: 0.040
-
Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer. 2018 04 15; 124(8):1701-1709.
Score: 0.039
-
Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. J Gastrointest Oncol. 2017 Dec; 8(6):990-997.
Score: 0.039
-
Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus. Clin Transl Radiat Oncol. 2017 Jun; 4:39-45.
Score: 0.037